|
Monday, 1 September |
|
17:00 –
20:00 |
Exhibitors’ open house
RECEPTION reception hall, 3rd floor
EXHIBITS, AND RESEARCH
PRESENTATIONS - POSTER VIEWING |
|
|
Poster Presentations |
|
18:00-20:00 |
CLINICAL AND SOCIAL BURDEN OF COPD — A Pre-Conference
Symposium
International
conference room 301, 3rd floor
Co-sponsored by Pfizer Pharmaceuticals Inc. and Nippon
Boehringer-Ingelheim Co., Ltd |
|
18:00-18:05 |
Introduction
Moderator: Shuzo Nishimura PhD, Professor, Faculty of Economics, Kyoto
University, Kyoto, Japan |
|
18:05-18:35 |
Current
Problem & Future Direction of Chronic Obstructive Pulmonary Disease (COPD)
Management in Japan
Speaker: Masakazu Ichinose MD, PhD, Professor, Third Department of Internal
Medicine, Wakayama Medical University, Wakayama, Japan
Chronic obstructive pulmonary disease (COPD)
is the most common chronic lung disease worldwide. During this
presentation the current
problem of COPD under-treatment and under-diagnosis in Japan, as well as
other countries, will be presented. |
|
18:35-18:45 |
Question and Answer |
|
18:45-19:15 |
Reducing the Disease Burden of COPD in Singapore: Current Status and
Progress
Speaker:
Ng Tze Pin MD PhD, Associate
Professor of Epidemiology, National University of Singapore, Singapore
COPD is a leading cause of death and hospitalizations in Singapore. COPD
mortality has decreased substantially but remains at high levels.
Anti-tobacco policies have reduced smoking prevalence, but current
management of COPD remains unsatisfactory. Innovative strategies to
reduce disease burden will be presented. |
|
19:15-19:25 |
Question and Answer |
|
19:25-19:40 |
Cost of
COPD and Cost-Effectiveness of Tiotropium in Japan
Speaker: Shuzo
Nishimura PhD, Professor, Faculty of Economics, Kyoto University, Kyoto,
Japan
During this presentation, the estimated cost of COPD in Japan will be
presented. The cost-effectiveness of Tiotropium, using the modeling
guidelines for COPD developed by Oostenbrink, Rutten-van Molken, and
McDonell [2002], will be discussed. Oostenbrink et al developed a Markov
model of exacerbations of COPD with and without medication.
|
|
19:40 – 20:00 |
Open Discussion |
|
|
|
